ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Avigan trial to stretch beyond June as Japan's coronavirus cases plunge

Exclusive: Participants have reached only 70% of target level

Clinical trials of Avigan began in March with the goal of testing 96 patients to examine its efficacy and safety. (Photo by Koji Uema) 

TOKYO -- Potential coronavirus treatment Avigan is now expected to take until July at the earliest to complete a clinical trial, further delaying government approval in Japan, Nikkei has learned.

A sharp decline in COVID-19 cases in Japan has made it difficult to secure enough patients for testing, according to people familiar with the matter.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more